Phuong N. Huynh

Array ( [id] => 9771200 [patent_doc_number] => 20140294864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-02 [patent_title] => 'DRUG CONJUGATE COMPOSITION' [patent_app_type] => utility [patent_app_number] => 14/304772 [patent_app_country] => US [patent_app_date] => 2014-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11252 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14304772 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10262409 [patent_doc_number] => 20150147406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-28 [patent_title] => 'Intraocular Formulation' [patent_app_type] => utility [patent_app_number] => 14/298418 [patent_app_country] => US [patent_app_date] => 2014-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 11667 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14298418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11318543 [patent_doc_number] => 09517276 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-13 [patent_title] => 'Compositions and methods for conjugating activatable antibodies' [patent_app_type] => utility [patent_app_number] => 14/296207 [patent_app_country] => US [patent_app_date] => 2014-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 16 [patent_no_of_words] => 44679 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 212 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14296207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12044581 [patent_doc_number] => 09822174 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-21 [patent_title] => 'Anti-VEGF antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same' [patent_app_type] => utility [patent_app_number] => 14/893813 [patent_app_country] => US [patent_app_date] => 2014-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 26 [patent_no_of_words] => 14224 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 1075 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14893813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16755353 [patent_doc_number] => 10973881 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => IgG4 Fc fragment comprising modified hinge region [patent_app_type] => utility [patent_app_number] => 14/894222 [patent_app_country] => US [patent_app_date] => 2014-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 8155 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14894222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10755975 [patent_doc_number] => 20160102127 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-14 [patent_title] => 'TARGETED MODULATION OF MACROPHAGES' [patent_app_type] => utility [patent_app_number] => 14/893514 [patent_app_country] => US [patent_app_date] => 2014-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 18161 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14893514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10945800 [patent_doc_number] => 20140348821 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-27 [patent_title] => 'Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer' [patent_app_type] => utility [patent_app_number] => 14/286796 [patent_app_country] => US [patent_app_date] => 2014-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2591 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14286796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10939383 [patent_doc_number] => 20140342405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-20 [patent_title] => 'VASCULAR ENDOTHELIAL GROWTH FACTOR 2' [patent_app_type] => utility [patent_app_number] => 14/278068 [patent_app_country] => US [patent_app_date] => 2014-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 53 [patent_no_of_words] => 101287 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14278068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15556813 [patent_doc_number] => 20200062818 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => BIFUNCTIONAL FUSION PROTEINS TO INHIBIT ANGIOGENESIS IN TUMOR MICROENVIRONMENT AND TO ACTIVATE ADAPTIVE IMMUNE RESPONSES AND THE GENES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 14/895959 [patent_app_country] => US [patent_app_date] => 2014-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14895959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12227534 [patent_doc_number] => 09914770 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-13 [patent_title] => 'Cloning, expression and purification method for the preparation of ranibizumab' [patent_app_type] => utility [patent_app_number] => 14/787981 [patent_app_country] => US [patent_app_date] => 2014-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 5132 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14787981 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9735983 [patent_doc_number] => 20140271695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-18 [patent_title] => 'IMMUNOGENIC LHRH COMPOSITIONS AND METHODS RELATING THERETO' [patent_app_type] => utility [patent_app_number] => 14/256043 [patent_app_country] => US [patent_app_date] => 2014-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7166 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14256043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14665103 [patent_doc_number] => 10370442 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-06 [patent_title] => vNAR recombinant monoclonal antibodies that neutralize vascular endophelial growth factor VEGF [patent_app_type] => utility [patent_app_number] => 15/304516 [patent_app_country] => US [patent_app_date] => 2014-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 68 [patent_figures_cnt] => 83 [patent_no_of_words] => 15431 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15304516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12106308 [patent_doc_number] => 09862778 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-09 [patent_title] => 'Assembly of bispecific antibodies' [patent_app_type] => utility [patent_app_number] => 14/251428 [patent_app_country] => US [patent_app_date] => 2014-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 32375 [patent_no_of_claims] => 71 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14251428 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10791845 [patent_doc_number] => 20160138002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-19 [patent_title] => 'ANTIBODY-UREASE CONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/783153 [patent_app_country] => US [patent_app_date] => 2014-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3511 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14783153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9785204 [patent_doc_number] => 20140302024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-09 [patent_title] => 'SERUM AMYLOID P-ANTIBODY FUSION PROTEINS' [patent_app_type] => utility [patent_app_number] => 14/223082 [patent_app_country] => US [patent_app_date] => 2014-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 17722 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14223082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11304824 [patent_doc_number] => 09512210 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-06 [patent_title] => 'Immunoglobulin constant region Fc receptor binding agents' [patent_app_type] => utility [patent_app_number] => 14/221148 [patent_app_country] => US [patent_app_date] => 2014-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 53 [patent_no_of_words] => 40783 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14221148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10905260 [patent_doc_number] => 20140308273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-16 [patent_title] => 'CELL CULTURE MEDIA AND METHODS OF ANTIBODY PRODUCTION' [patent_app_type] => utility [patent_app_number] => 14/211467 [patent_app_country] => US [patent_app_date] => 2014-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30259 [patent_no_of_claims] => 117 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14211467 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9838512 [patent_doc_number] => 20150030593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-29 [patent_title] => 'COMPOSITIONS OF PENETRATION-ENHANCED TARGETING PROTEINS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/214463 [patent_app_country] => US [patent_app_date] => 2014-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 54966 [patent_no_of_claims] => 54 [patent_no_of_ind_claims] => 25 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14214463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9785216 [patent_doc_number] => 20140302037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-09 [patent_title] => 'BISPECIFIC-Fc MOLECULES' [patent_app_type] => utility [patent_app_number] => 14/210178 [patent_app_country] => US [patent_app_date] => 2014-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 17424 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14210178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10670903 [patent_doc_number] => 20160017047 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-21 [patent_title] => 'CD20-BINDING IMMUNOTOXINS FOR INDUCING CELLULAR INTERNALIZATION AND METHODS USING SAME' [patent_app_type] => utility [patent_app_number] => 14/774609 [patent_app_country] => US [patent_app_date] => 2014-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 27583 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14774609 [rel_patent_id] =>[rel_patent_doc_number] =>)